DRMA — Dermata Therapeutics Share Price
0.000.00%
Last trade - 00:00- $1.34m
- -$3.39m
- 12
- 53
- 44
- 29
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.38 | ||
| Price to Tang. Book | 0.38 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -235.5% | ||
| Return on Equity | -146.08% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, DMT310, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 50 million patients. Its second product candidate utilizing its Spongilla technology is DMT410, its combination treatment. DMT410 is intended to consist of one treatment of its proprietary sponge powder followed by one topical application of botulinum toxin for delivery into the dermis.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- December 8th, 2014
- Public Since
- August 13th, 2021
- No. of Shareholders
- 65
- No. of Employees
- 8
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 562,175
- Address
- 3525 Del Mar Heights Rd., #322, SAN DIEGO, 92130
- Web
- https://www.dermatarx.com/
- Phone
- +1 8582230882
- Contact
- Sean Proehl
- Auditors
- Moss Adams LLP Seattle, Washington
Upcoming Events for DRMA
Similar to DRMA
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Dermata Therapeutics share price?
As of Today at 20:16 UTC, shares in Dermata Therapeutics are trading at $2.56. This share price information is delayed by 15 minutes.
How has the Dermata Therapeutics share price performed this year?
Shares in Dermata Therapeutics last closed at $2.56 and the price had moved by -91.45% over the past 365 days. In terms of relative price strength the Dermata Therapeutics share price has underperformed the S&P500 Index by -93.19% over the past year.
What are the analyst and broker recommendations for Dermata Therapeutics?
The overall consensus recommendation for Dermata Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Dermata Therapeutics dividend yield?
Dermata Therapeutics does not currently pay a dividend.
Does Dermata Therapeutics pay a dividend?
Dermata Therapeutics does not currently pay a dividend.
When does Dermata Therapeutics next pay dividends?
Dermata Therapeutics does not currently pay a dividend.
How do I buy Dermata Therapeutics shares?
To buy shares in Dermata Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Dermata Therapeutics?
As of the previous close price of $2.56, shares in Dermata Therapeutics had a market capitalisation of $1.44m.
Where are Dermata Therapeutics shares listed?
Here are the trading details for Dermata Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: DRMA
What kind of share is Dermata Therapeutics?
Based on an overall assessment of its quality, value and momentum Dermata Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Dermata Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Dermata Therapeutics is $10.00. That is 290.63% above the last closing price of $2.56.
Analysts covering Dermata Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$16.17 for the next financial year.
What is the trend in the Dermata Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Dermata Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -75.98%.
As of the last closing price of $2.56, shares in Dermata Therapeutics were trading -69.22% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Dermata Therapeutics PE Ratio?
The Dermata Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.56.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Dermata Therapeutics?
We do not have data on Dermata Therapeutics' directors